WEBULL
WebtradeDownload

Is BeOne Medicines (ONC) Undervalued As Earnings Estimates Jump?

Simply Wall St · 2d ago

BeOne Medicines (ONC) drew fresh attention after Zacks moved the stock to its top Rank #1 list, following a 15.2% increase in the firm’s current year earnings estimate.

Recent trading tells a story of rebuilding confidence. BeOne Medicines’ share price has pulled back 1.34% over the last day to US$369.06, yet the 90 day share price return of 18.28% and 3 year total shareholder return of 123.39% point to momentum that has been developing over a longer stretch, even though the 5 year total shareholder return is slightly negative at 2.59%.

Scan beyond BeOne Medicines and see how it stacks up against 33 healthcare AI stocks capturing attention around cancer and healthcare breakthroughs.

The recent run in BeOne Medicines, alongside a sharp reset higher in earnings expectations, raises a simple tension. Is the bigger payoff still ahead, or has the stock already banked most of the good news on valuation?

Most Popular Narrative: 15% Undervalued

On the most followed narrative, BeOne Medicines' fair value of $433.02 sits above the last close at $369.06, which puts the recent Zacks upgrade in context and focuses attention on how much of the oncology pipeline is already reflected in that gap.

The company's robust pipeline, including multiple late-stage oncology assets (over 20 Phase III trials and >10 proof-of-concept readouts expected in the next 18 months), leverages internal R&D capabilities and the GlueXplorer™ platform to rapidly develop targeted, personalized medicines, which are well aligned with the shift toward precision therapeutics and support long-term earnings and margin expansion as products commercialize.

See why 20 investors see BeOne Medicines as 15% undervalued.

Result: Fair Value of $433.02 (UNDERVALUED)

Still, two pressure points could quickly challenge the BeOne Medicines upside story: heavy reliance on BRUKINSA and any regulatory or pricing hit in key markets.

Find out about the key risks to this BeOne Medicines narrative.

Another View: What BeOne Medicines’ P/E Is Telling You

There is a very different read on BeOne Medicines when switching from fair value estimates to simple market multiples. The shares trade on a P/E of 64x, compared with 28.2x for peers, 17.9x for the wider US biotech group, and a fair ratio of 34.3x that the market could move toward. That kind of gap can either compress sharply or hold if earnings keep catching up, so which scenario do you think you are really betting on?

For a closer look at how this pricing stacks up against fundamentals, take a moment with See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:ONC P/E Ratio as at Oct 2026
NasdaqGS:ONC P/E Ratio as at Oct 2026

Next Steps

If the mixed mood on BeOne Medicines has you on the fence, use it as a prompt to run the numbers yourself and decide quickly. To see what the market-friendly upside case looks like in more detail, take a closer look at the 3 key rewards.

Ready for more ideas beyond BeOne Medicines?

Do not stop with BeOne Medicines. Use the screener to surface fresh opportunities that fit your style before other investors move on them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.